Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the MAGNITUDE® Bioresorbable Drug-Eluting Scaffold (BRS)in the Treatment of Patients With Below the Knee Disease in Australia

NCT06075940 is registered in ClinicalTrials.gov with R3 Vascular Inc. as lead sponsor.

NCT NCT06075940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06075940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the MAGNITUDE® Bioresorbable Drug-Eluting Scaffold (BRS)in the Treatment of Patients With Below the Knee Disease in Australia
Lead sponsor
R3 Vascular Inc.
Phase
Not applicable
Overall status
Recruiting
Start date
March 4, 2024
Completion date
December 31, 2030
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

critical limb ischemia, critical limb-threatening ischemia, critical lower limb ischemia